The Filing Desk

Burning Rock Biotech

BNR · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

BNR · Last close · November 19, 2026
$13.32

Burning Rock Biotech's revenue rose 4.6% to CN¥540 million in fiscal 2025. Its operating margin was −10.2%, up from −69.3% a year earlier. Free cash flow was −CN¥34 million.

Burning Rock Biotech Limited Latest fiscal year ended December 31, 2025 20-F filed April 28, 2026 · 0001193125-26-183377 Updated
Revenue
CN¥540M
4.6%
Operating margin
−10.2%
59.2 pts
Net income
−CN¥55M
 
Free cash flow
−CN¥34M
 
Return on equity
−9.9%
41.5 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Burning Rock Biotech is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in CNY, as it reports them: they aren't converted to US dollars. Return on capital for fiscal 2025 is blank: invested capital is small next to total assets (cash nearly matches equity and debt), so the ratio isn't meaningful.

What Burning Rock Biotech does

Burning Rock Biotech is a cancer diagnostics company in China. It uses next-generation sequencing, or NGS, a way of reading many genes at once, to test tumor tissue and blood samples. Doctors use its tests to choose a treatment for a cancer patient. It also sells tests that look for traces of cancer left after surgery, and it is developing blood tests meant to find several cancers early.

It sells its tests in two ways. Hospitals across China send samples to its central laboratory, which runs the tests and issues reports. It also helps hospitals set up their own laboratories, installs the equipment and trains staff, and then sells them reagent kits, the chemicals used to run the tests, on a recurring basis. At the end of 2025 it worked with 94 hospitals in 43 cities this way, and it says it is now putting more effort into this hospital model. It also provides laboratory services to drug companies for their clinical trials.

Burning Rock recorded revenue of US$77.2 million in 2025, and its gross profit margin was 74.7%. Its early detection test, OverC, received Breakthrough Device Designation from both the FDA and China's drug regulator, the NMPA, in 2023, and it has signed contracts with a small number of pilot hospitals to sell it. The company runs its business in China through a variable interest entity, or VIE: a Chinese company it controls by contract rather than by owning it, because Chinese rules bar foreign investors from genomic diagnosis.

Its biggest risks, as it describes them

  • It has a history of net losses and may not reach or keep profitability.
  • Hospitals and doctors may not keep using its therapy selection tests, and revenue from partner hospitals can swing with their budgets.
  • It may fail to develop and sell its early cancer detection and residual disease tests on time, or at all.
  • It relies on a small number of suppliers for some laboratory equipment and supplies.
  • It runs its business through contracts with a VIE in China, which may not give the same control as owning it and may not be enforceable under Chinese law.
From Burning Rock Biotech's annual report on Form 20-F, filed April 28, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
CNY billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
CNY billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Burning Rock Biotech lost money in fiscal 2025: a net loss of CN¥55 million.

Diluted earnings per share
CNY per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
CNY billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
CNY billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,495906615520478
Debt incl. finance leases20002
Net debt (negative means net cash)−1,493−906−615−520−477
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−518.9x−1,117.9x——−1,828.2x
Current ratio4.9x3.1x3.4x2.9x3.0x
Quick ratio4.6x2.7x3.1x2.7x2.8x
CNY millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
CNY billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
CNY billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
CNY billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−53.7%−23.0%−1.6%
Altman Z''−9.52−12.40−11.46
Accruals ratio−30.3%−26.4%−3.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't rise———
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Burning Rock Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Burning Rock BiotechFY254.6%−10.2%−6.2%———
VeracyteFY2516.0%11.2%24.5%6.1%−4.6x6Compare
Starling OncologyFY2527.8%−7.2%−5.5%−75.7%—3Compare
Concord Medical ServicesFY2519.9%−56.8%−56.1%−4.1%—6Compare
GeneDxFY2540.0%−3.1%3.3%−5.3%—6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue209382430508563537516540
Revenue growth—82.7%12.6%18.1%10.9%−4.6%−4.0%4.6%
Gross profit135273314364380363362403
Research and development105157264368422347232166
Operating income−161−169−412−797−980−669−358−55
Net income−178−169−407−797−971−654−347−55
Diluted EPS (CNY)−10.38−14.230.000.00————
Diluted shares (millions)222400————
Cash flow
Cash from operations−149−228−74−478−457−256−92−28
Capital expenditure23436020462855
Free cash flow−172−271−134−682−519−264−98−34
Dividends paid00000000
Share buybacks04000000
Acquisitions00000000
Stock-based compensation52317328232726115614
Balance sheet at fiscal year end
Cash and short-term investments934082,2571,495906615520478
Debt incl. finance leases—21720002
Total assets—8482,6632,2791,5881,040885820
Total liabilities—212242433429272304285
Shareholders' equity−604−8922,4211,8451,158768581535
Margins and ratios
Gross margin64.7%71.6%73.0%71.7%67.5%67.6%70.3%74.7%
Operating margin−77.3%−44.3%−95.9%−156.9%−174.1%−124.5%−69.3%−10.2%
Net margin−85.0%−44.3%−94.7%−156.9%−172.4%−121.6%−67.2%−10.3%
Free cash flow margin−82.3%−71.0%−31.1%−134.3%−92.1%−49.1%−18.9%−6.2%
Rule of 40 (growth + FCF margin)—11.7%−18.5%−116.2%−81.2%−53.7%−23.0%−1.6%
Return on capital———−240.6%−255.8%−260.3%−263.6%—
Return on equity——−53.2%−37.4%−64.7%−67.8%−51.4%−9.9%
Return on assets——−23.2%−32.2%−50.2%−49.8%−36.0%−6.5%
Net debt to EBITDA————————
CNY millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, CNY millions)
Source: Burning Rock Biotech's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Burning Rock Biotech.